News | Stents Peripheral | October 01, 2015

Stentys Receives CE Mark for Self-Apposing Stent in Lower Limb Artery Disease

Trial data found paclitaxel-eluting stent successfully prevented foot amputation in 99 percent of patients treated for critical limb ischemia

Stentys, CE Mark for self-apposing stent, lower limb artery disease, below-the-knee arteries, critical limb ischemia, PES BTK-70 trial

Image courtesy of Stentys

October 1, 2015 — Stentys announced that the company’s drug-eluting stent received CE Mark for treatment of below-the-knee (BTK) arteries. The approval makes it the first self-expanding and drug-eluting stent with regulatory approval in Europe for this indication.

The CE Mark was obtained following the results achieved by the device in the PES BTK-70 study in which the product prevented foot amputation in 99 percent of the 70 patients treated for critical limb ischemia (CLI).

The most severe cases of CLI, in which tissue of the foot or ankle does not receive a sufficient supply of oxygen and begins to die, often require amputation. To prevent this outcome, surgeons open up the artery with balloons and frequently implant stents. Approximately 25 percent of diabetics globally suffer from CLI and, according to the International Diabetes Foundation (IDF), the worldwide diabetic population is projected to increase from 387 million in 2014 to nearly 600 million individuals by 2035.

The PES BTK-70 trial treated 70 patients suffering from CLI of class 4 and 5 in the Rutherford scale with a Stentys paclitaxel-eluting stent from January 2012 to May 2013 in five hospitals. The primary endpoint was the 12-month primary patency rate defined as absence of restenosis (≥50 percent) or occlusion within the originally treated lesion based on angiography verified by Core Lab. At 12 months, the primary patency rate was 73 percent, freedom from target lesion revascularization was 79 percent and freedom from amputation was 99 percent.

For more information: www.stentys.com

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Overlay Init